Maël Heiblig

Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*

Sophie Georgin‐Lavialle, Benjamin Terrier, Alexis F. Guédon et al. · British Journal of Dermatology · 2021 · 387 citations · Full text

Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study

Maël Heiblig, Marcela A. Ferrada, Matthew T. Koster et al. · Blood · 2022 · 194 citations · Full text

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Lynn Quek, Muriel D. David, Alison Kennedy et al. · Nature Medicine · 2018 · 193 citations · Full text

Hematological Malignancy, Clonal Heterogeneity, Medicine +11

Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Thibault Comont, Maël Heiblig, Étienne Rivière et al. · British Journal of Haematology · 2021 · 157 citations · Full text

Hematological Malignancy, E1 Enzyme, Autoimmune Disease +13

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience

Ava Diarra, Nicolas Duployez, Élise Fournier et al. · Blood Advances · 2021 · 138 citations · Full text